admin

Home/admin

About admin

This author has not yet filled in any details.
So far admin has created 18 blog entries.

Отворено писмо от името на Сдружение Клуб Млад Онколог България

В това отворено писмо бихме искали да изложим становището на лекарите медицински онколози, членуващи в Клуб Млад Онколог относно наскоро въведените лимити за медицински дейности и лекарства за онкологично болни пациенти. Противно нa тезата, че „няма как да стане по-лошо здравеопазването в България“, НЗОК, БЛС и МЗ ни демонстрират противното! Отговорността за лечението и живота [...]

By | 2017-05-20T17:58:22+00:00 April 4th, 2015|Uncategorized|Comments Off on Отворено писмо от името на Сдружение Клуб Млад Онколог България

Approval concerns filgrastim-sndz intended for patients with cancer who receive myelosuppressive chemotherapy

Date: 10 Mar 2015 Topic: Palliative and supportive care On 6 March 2015 the US Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. Sandoz Inc.’s Zarxio is biosimilar to Amgen Inc.’s Neupogen (filgrastim), which was originally licensed in 1991. Zarxio is approved for the same indications [...]

By | 2015-03-25T22:09:53+00:00 March 25th, 2015|Uncategorized|Comments Off on Approval concerns filgrastim-sndz intended for patients with cancer who receive myelosuppressive chemotherapy

Whole Genome Sequencing of Pancreatic Ductal Adenocarcinomas

Pancreatic cancer mutational landscape Date: 04 Mar 2015 Topic: Translational research / Gastrointestinal cancers The researchers performed whole-genome sequencing and copy number variation analysis of 100 samples to reveal mutational landscape of pancreatic ductal adenocarcinomas. Their findings led to classification of pancreatic ductal adenocarcinomas into 4 subtypes with potential clinical utility. The team of international [...]

By | 2017-05-20T17:58:22+00:00 March 12th, 2015|Uncategorized|Comments Off on Whole Genome Sequencing of Pancreatic Ductal Adenocarcinomas

New research reveals a connection between ccRCC and exposure to an ingredient in some herbal remedies

Date: 03 Nov 2014 Topic: Genitourinary cancers / Translational research New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between clear cell renal cell cancer (ccRCC) and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published in Nature Communications, have important implications for public [...]

By | 2014-11-10T00:43:37+00:00 November 10th, 2014|Uncategorized|Comments Off on New research reveals a connection between ccRCC and exposure to an ingredient in some herbal remedies

New findings suggest why patients with early-stage tumours and EGFR mutations have worse outcomes with erlotinib

Date: 30 Oct 2014 Topic: Translational research / Lung and other thoracic tumours / Anticancer agents & Biologic therapy David Carbone David Carbone Mutations in the epidermal growth factor receptor (EGFR) are the most common actionable genetic abnormalities yet discovered in lung cancer. However, targeting these mutations with kinase inhibitors is not curative in advanced [...]

By | 2014-11-10T00:40:02+00:00 November 10th, 2014|Uncategorized|Comments Off on New findings suggest why patients with early-stage tumours and EGFR mutations have worse outcomes with erlotinib

Novel Immunotherapy Vaccine May Decrease Recurrence in HER2 Positive Breast Cancer Patients

Women who received trastuzumab as part of standard treatment show greatest benefit Date: 10 Sep 2014Topic: Breast cancer / Immuno-oncology A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is administered after completing trastuzumab treatment. [...]

By | 2014-10-19T14:02:29+00:00 September 23rd, 2014|Uncategorized|Comments Off on Novel Immunotherapy Vaccine May Decrease Recurrence in HER2 Positive Breast Cancer Patients

New Guideline on Treating Women with Advanced, HER2-Negative Breast Cancer

ASCO issues evidenced-based information for management of patients with HER2 negative or HER2 status unknown advanced breast cancer Date: 09 Sep 2014 Topic: Breast cancer / Anticancer agents & Biologic therapy   The American Society of Clinical Oncology (ASCO) issued on 2 September 2014 a new clinical practice guideline on chemotherapy and targeted therapy for [...]

By | 2017-05-20T17:58:22+00:00 September 23rd, 2014|Uncategorized|Comments Off on New Guideline on Treating Women with Advanced, HER2-Negative Breast Cancer